ANNOUNCEMENT NO. 294 9 October 2025 Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025 at 5.30 p.m. at Nordsjællands KonferenceCenter. At the Annual General Meeting, the Board of Directors' report on the company's activities during the past year was presented, the annual report for 2024/25 was approved, and the Board of Directors and the Executive Board were granted discharge. The Annual General Meeting approved the proposal of the Board of Dire ...

ANNOUNCEMENT NO. 291 11 September 2025 Guidance for the 2025/26 financial year ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside information. For 2025/26, ChemoMetec expects revenue in the range of DKK 545-565 million (2024/25: DKK 495.6 million) and EBITDA in the range of DKK 295-315 million (2024/25: DKK 258.0 million). The annual report for 2024/25, which is released along with this announcement, sets out the underlying assumptions a ...

文章核心观点 公司2024/25财年初步营收约为4.96亿丹麦克朗，高于此前宣布的4.7 - 4.9亿丹麦克朗，2024/25年年报定于2025年9月11日发布 [1] 公司信息 - 公司为ChemoMetec A/S，1997年成立，在纳斯达克哥本哈根证券交易所上市，网址为www.chemometec.com [3] - 公司开发、制造和销售用于细胞计数及其他多种测量的仪器，产品面向全球制药、生物技术和农业行业销售，客户包括一些全球领先的制药公司 [2] 公司管理层 - 首席执行官为Martin Helbo Behrens，首席财务官为Kim Nicolajsen，联系电话均为(+45) 48 13 10 20 [2]